Phase 2a/b study for safety and efficacy of MT-3724 in Subjects with Relapsed or Refractory Follicular Lymphoma
Latest Information Update: 21 May 2021
At a glance
- Drugs MT 3724 (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment, according to a Molecular Templates, Inc. media release, as the company has decided to discontinue the MT-3724 development program.
- 13 Jan 2021 New trial record
- 08 Dec 2020 trial design presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.